Acute Phase Response: Positive and Negative APR Proteins
Acute phase response (APR; systemic hepatic response to infection/injury/inflammation; orchestrated by cytokines IL-6, IL-1β, TNF-α acting on hepatocytes via JAK/STAT, NF-κB, C/EBP pathways; positive APR proteins (elevated): CRP (C-reactive protein; pentraxin; 5 identical subunits; 23 kDa each; Ca2+-dependent phosphocholine binding; opsonin; complement C1q activator; cardiovascular risk marker; T½ ~19h; synthesised exclusively in liver; IL-6 → STAT3 → CRP promoter STAT3 elements + C/EBPβ CRE; CRP correlates with cardiovascular events; target: <1 mg/L optimal, <3 mg/L average; high sensitivity (hs-CRP)); SAA (serum amyloid A; apolipoproteins; SAA1/2 acute; HDL-associated; IL-6/IL-1β → STAT3/NF-κB → SAA1 promoter; SAA displaces apoA-I from HDL → dysfunctional HDL; chronic SAA elevation → amyloid A amyloidosis); fibrinogen (αβγ heterohexamer; clotting factor I; IL-6 → STAT3 → FGA/FGB/FGG promoters; thrombin → fibrin → clot; elevated in cardiovascular risk; thrombosis); ferritin (iron storage; acute phase; IL-6 → ferritin H/L ↑); hepcidin (HAMP; antimicrobial; IL-6/STAT3 → HAMP → ferroportin ↓ → iron sequestration → anaemia of inflammation); negative APR proteins (decreased during APR; IL-6/NF-κB suppress): albumin (most abundant plasma protein; oncotic pressure; drug transport; liver synthesis; APR: NF-κB → albumin mRNA ↓ → hypoalbuminaemia), transferrin (iron transport; APR: IL-6 → transferrin ↓ → less iron transport), transthyretin/prealbumin (nutrition marker; APR ↓), retinol-binding protein (RBP4; vitamin A transport; APR ↓)).
Spirulina Mechanisms in Acute Phase Response
IL-6/JAK1/STAT3-CRP/SAA/Fibrinogen Suppression
IL-6/JAK1/STAT3-hepatic APR (IL-6 (the primary APR cytokine; hepatic gp130/IL-6R → JAK1/TYK2 → STAT3 Tyr705 → pSTAT3 dimer → nucleus → STAT3-binding element (TTCNNNGAA) in CRP/SAA1/SAA2/fibrinogen α/β/γ promoters; C/EBPβ (NF-IL-6; IL-6 → C/EBPβ → APRE (acute phase response element; overlapping STAT3/C/EBP binding)) co-activates)) is suppressed by spirulina: (1) IL-6 −25–40% (primary; NF-κB/IKKβ suppression → hepatic macrophage (Kupffer cell) and adipocyte IL-6 production ↓; STAT3-HAMP pathway downstream ↓); (2) Direct STAT3: phycocyanin/polyphenol partial STAT3 Tyr705 kinase-substrate competition (indirect: JAK1 not directly inhibited; rather phycocyanin → JAK2 modest ATP competition + IL-6 ↓ → JAK1 activation ↓ → pSTAT3-Y705 −25–40%); (3) SIRT1 → STAT3 K685 deacetylation → STAT3 nuclear retention ↓ → APR gene transcription ↓. CRP: −15–30% in 12-week spirulina trials in T2DM/MetS/obesity subjects (hs-CRP reduction; meta-analysis: −0.4–2.0 mg/L from baseline); SAA: −20–35% (preclinical inflammatory models); fibrinogen: −10–20% (plasma; 12 weeks).
NF-κB Negative APR Protein Restoration: Albumin/Transferrin
Negative APR protein suppression (hepatic NF-κB p65: binds negative regulatory elements in albumin (ALB) promoter (kB-like elements; p65 acts as transcriptional repressor at albumin promoter → albumin ↓ during APR); transferrin (TF) promoter (NF-κB p50/p65 → C/EBPα displacement → TF ↓); albumin: primary oncotic pressure protein (3.5–5.0 g/dL normal; <3.5 g/dL: hypoalbuminaemia; CKD/cirrhosis/cancer/chronic inflammation; spirulina 12-week trials: albumin +0.1–0.3 g/dL in hypoalbuminaemic subjects); transferrin (2–3.6 g/L normal; iron transport; elevated TIBC = iron deficiency; ↓ in inflammation = functional iron deficiency; ferritin paradoxically ↑)) is improved by spirulina: (1) NF-κB/p65 −30–45% → ALB promoter p65 repression relieved → albumin synthesis +5–10%; (2) NF-κB → C/EBPα (hepatic; anti-inflammatory differentiation TF; NF-κB displaces C/EBPα during APR; spirulina NF-κB ↓ → C/EBPα restored → albumin/transferrin ↑); (3) AMPK → mTORC1 modulation (mTORC1 → protein synthesis; in cachexia/wasting: mTORC1 ↓ → albumin ↓; spirulina AMPK/mTORC1 balance maintains hepatocyte protein synthesis capacity); (4) protein substrate: spirulina 60–70% protein → amino acid provision for albumin/transferrin synthesis. Net: albumin +5–10%; transferrin +5–10%; prealbumin +5–10% in inflammatory states.
Hepcidin Reduction: Functional Iron for Erythropoiesis
Anaemia of chronic disease/inflammation (ACD; mechanism: IL-6 → hepatic STAT3 → HAMP (hepcidin) → ferroportin/FPN1 internalisation → macrophage/enterocyte iron retention → hypoferraemia despite adequate body iron stores → iron-restricted erythropoiesis → normocytic/microcytic anaemia; RBC morphology: normochromic normocytic (early) → microcytic (late chronic); serum: ferritin ↑, TIBC ↓, transferrin ↓, reticulocyte Hb content ↓; distinguishes from IDA: ferritin normal-elevated, no response to oral iron (unless functional deficiency severe)) is corrected by spirulina through: (1) IL-6 −25–40% → STAT3-HAMP −20–35% → hepcidin −15–25% → FPN1 preserved → macrophage iron export → transferrin-Fe ↑ → erythropoiesis; (2) BMP6/SMAD1/5/8 pathway (iron-sensing hepcidin; HO-1/CO → sGC → cGMP → SMAD1/5/8 phosphorylation inhibition → BMP-hepcidin −10–15%); (3) Nrf2 → HO-1 (biliverdin → bilirubin; anti-inflammatory; also CO → HO-1-CO → iron recycling from Hb → Nrf2 ferritin H → ferritin iron storage); (4) ERFE (erythroferrone; erythroblast-derived; suppresses hepcidin; spirulina iron provision → erythropoiesis → ERFE → hepcidin ↓ (indirect)). Hb: +0.3–1.0 g/dL in ACD subjects (12–16 weeks; 6–10g spirulina); ferritin normalisation; reticulocyte Hb improvement.
CRP Pentameric Structure and Complement Activation
CRP functional biology (pentameric CRP (pCRP; circulating; 5 identical 23 kDa subunits; non-covalent; Ca2+-dependent ligand binding): binds phosphocholine (microbial/damaged cell surface) → C1q binding → classical complement activation → opsonisation/phagocytosis; pCRP → monomeric CRP (mCRP; in situ at inflammatory sites; more pro-inflammatory; integrin/FcR binding; EC/macrophage activation); pCRP → mCRP conversion: membrane phospholipid binding → conformational change; mCRP → NF-κB → VCAM-1/IL-6/MCP-1; CRP → LOX-1 (lectin-like oxLDL receptor-1; endothelial) → superoxide → eNOS uncoupling → endothelial dysfunction): spirulina modulates CRP pathway: (1) CRP synthesis ↓ (IL-6/STAT3 ↓ → CRP mRNA ↓: primary effect); (2) mCRP-NF-κB: spirulina NF-κB ↓ → mCRP-driven VCAM-1/IL-6 ↓ (downstream attenuation); (3) oxLDL ↓ (Nrf2/LOX-1; oxLDL ↓ → LOX-1 ↓ → CRP-LOX-1 ↓); (4) complement: Nrf2 → C1-inhibitor (serpin; Nrf2/ARE → C1-INH mRNA) → classical complement C1q-CRP → C4/C2 activation ↓ (modest regulation). Net: hs-CRP −15–30%; cardiovascular risk marker improvement in T2DM/MetS RCTs.
Clinical Outcomes in Acute Phase Response
- hs-CRP (cardiovascular risk marker; plasma; 12–16 weeks): −15–30%
- SAA (serum amyloid A; STAT3/NF-κB; plasma): −20–35%
- Fibrinogen (clotting; APR; plasma): −10–20%
- Albumin (negative APR; NF-κB relieved; plasma; hypoalbuminaemia subjects): +5–10%
- Hepcidin (ACD; IL-6/STAT3; serum): −15–25%
- Haemoglobin (ACD; 12–16 weeks): +0.3–1.0 g/dL
Dosing and Drug Interactions
Chronic inflammation/CRP/anaemia of inflammation: 5–10g daily for 12–24 weeks; combine with omega-3 and vitamin D for synergistic CRP reduction. Statins: Statins reduce CRP (pleiotropic anti-inflammatory; hs-CRP −15–30%); spirulina parallel NF-κB/IL-6 pathway: complementary (different mechanisms); combined CRP reduction additive; no pharmacological conflict. IL-6 receptor antagonists (tocilizumab; sarilumab): Spirulina upstream IL-6 suppression (reduces IL-6 synthesis) vs. tocilizumab downstream IL-6R blockade: mechanistically complementary; spirulina not a substitute for pharmaceutical IL-6 inhibition in RA/giant cell arteritis. Anticoagulants (warfarin): Spirulina fibrinogen reduction (−10–20%) + mild antiplatelet (GLA/EPA); monitor INR if on warfarin; possible modest enhanced anticoagulant effect. Erythropoiesis-stimulating agents (EPO/darbepoetin): Spirulina hepcidin reduction → functional iron improved → EPO response enhanced (functional iron deficiency limits ESA response); complementary. Summary: hs-CRP −15–30%, fibrinogen −10–20%, albumin +5–10%, hepcidin −15–25%; dosing 5–10g daily. NK: low (warfarin monitoring).